Brief: Sequana Medical: Positive Results From Phase 1 Clinical Trial Of Second-Generation DSR Product

Sequana Medical NV

01/03/2023 06:11

March 1 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES POSITIVE RESULTS FROM CHIHUAHUA,
PHASE
1 CLINICAL TRIAL OF SECOND-GENERATION DSR PRODUCT FOR CONGESTIVE
HEART FAILURE
    * ON TRACK TO FILE INDIAPPLICATIONTO US FDA IN Q1 2023
    * START OFMOJAVE, A US MULTI-CENTER RANDOMIZED CONTROLLED
PHASE
1/2A CLINICAL TRIAL OF DSR 2.0,PLANNED FORQ2 2023
    * PHASE 1 CLINICAL TRIAL (CHIHUAHUA) DEMONSTRATES THAT
SINGLE DOSE
OF SECOND-GENERATION DSR PRODUCT (DSR 2.0) IS SAFE
ANDWELL-TOLERATED, AND INDICATES A COMPELLING DOSING PROFILE

Source text for Eikon:  ID:nGNX2fl8g7 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))